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Background: Despite the evidence that phosphate binder (PB) is associated with improved outcomes many
hemodialysis patients do not adhere to prescribed PB regimen. Therefore, barriers to PB adherence should be
identified and eliminated. The purpose of this study was to evaluate PB adherence among hemodialysis patients
and to explore potentially modifiable factors associated with low PB adherence.
Methods: A cross-sectional study (502 patients) was performed in four dialysis units in Salvador, Brazil, using data
from the second phase of the Prospective Study of the Prognosis of Chronic Hemodialysis Patients (PROHEMO).
Patients were categorized as adherent or non-adherent to PB based on their responses to a semi-structured
questionnaire.
Results: Non-adherence to PB was observed for 65.7% of the patients. After adjustments for numerous covariates,
cerebrovascular disease (odds ratio (OR), 3.30; 95% confidence interval (CI), 1.03-10.61), higher PTH (OR per each
300 pg/mL, 1.14; 95% CI, 1.01-1.28), lack of comprehension of the appropriate time to use PB (OR, 7.09; 95% CI,
2.10-23.95) and stopping PB use after feeling better (OR, 4.54; 95% CI, 1.45-14.25) or feeling worse (OR, 11.04;
95% CI, 1.79- 68.03) were significantly associated with PB non-adherence. By contrast, the adjusted odds of PB
non-adherence were lower for patients with more years on dialysis (OR by each 2 years, 0.87; 95% CI, 0.80-0.95),
with serum phosphorus above 5.5 mg/dL (OR, 0.53; 95% CI 0.34-0.82), who referred that were encouraged by the
dialysis staff to be independent (OR, 0.52; 95% CI 0.30-0.90), and reported that the nephrologist explained how PB
should be used (OR, 0.20; 95% CI 0.05-0.73).
Conclusion: The results of the present study are encouraging by showing evidence that improvement in the care
provided by the dialysis staff and the attending nephrologist may play an important role in reducing the high
prevalence of non-adherence to PB in maintenance hemodialysis patients. A new questionnaire is presented and
may help to evaluate systematically the patients regarding PB adherence in hemodialysis setting.
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The deterioration of kidney function is accompanied by
disturbances in mineral metabolism, including decreased
vitamin D and calcium levels and increased parathyroid
hormone (PTH) and phosphorus levels, which begin in the
early stages of the disease [1]. In patients on dialysis, ab-
normalities in serum phosphorus, calcium and PTH levels
have been shown to be associated with increased cardio-
vascular mortality [2-6]. Although all of these abnormal-
ities must be controlled, phosphorus level control has
received special attention because of the strong evidence
linking hyperphosphatemia and cardiovascular mortality
[2]. Therefore, to improve survival, current guidelines ad-
vocate more strict phosphorus control than in the past,
and this control is usually achieved by optimizing renal re-
placement therapy, restricting dietary phosphorus intake
and using a phosphorus binder [3,4].
For patients on renal replacement therapy, it is import-
ant to avoid non-adherence to the dialysis schedule and to
adjust the parameters to improve phosphorus removal in
hemodialysis therapy [7-10]. With regard to phosphorus
intake, phosphorus restriction can result in protein res-
triction, and thus, attention is required to maintain an
adequate protein intake [11]. A significant proportion of
phosphorus intake often comes from the phosphate salts
that are used as additives and preservatives, especially in
processed and fast foods. Thus, dietary counseling to avoid
food with high phosphorus content, while ensuring ad-
equate protein intake, can help in the management of
serum phosphorus concentration [8]. However, despite the
use of optimized renal replacement therapy and adequate
dietary phosphorus restriction, most patients must still use
a phosphate binder to control their phosphorus levels [8].
It is important to note that there is evidence that phos-
phate binders are associated with longer survival because
they allow for less severe protein restriction, and conse-
quently, they are associated with improved nutritional
status [12,13]. The use of a phosphate-restricted diet, in
combination with an oral phosphate binder, has become
well established in the management of patients on dialysis,
although there is not yet consensus among experts
regarding this. It is important to note that according
to the K/DIGO Work Group, the strength of indication
for prescribing phosphate binder to patients with CKD
stage 5D is graded as Level 2 (suggested) and the evidence
quality grade is B (moderate) [8,12,13].
Although the use of phosphate binders has become well
established, many patients on dialysis do not take these
drugs as prescribed. Therefore, the barriers to phosphate
binder adherence should be considered. The use of phos-
phate binders is associated with side effects, most com-
monly of gastrointestinal origin, and these side effects can
interfere with social habits and with individual lifestyles,
and the use of phosphate binders also increases theburden of daily pills and treatment costs [8,14-16]. Studies
have shown that the prevalence of non-adherence to
phosphate binders varies from 22% to 74% (mean 51%)
[16]. It is important to note that this large variability can
be explained by the different methodologies used to meas-
ure adherence in these studies, with most of the studies
inappropriately using the serum phosphorus level to
measure adherence [16].
Given the necessity of phosphorus control and consider-
ing the benefits of the nutritional improvement possible
with the use of phosphate binders by hemodialysis pa-
tients, as well as that the newer phosphate binders are
very expensive, it is important to explore the barriers to
phosphate binder adherence and to consider strategies
to avoid non-adherence. The objectives of this study were
to evaluate adherence to phosphate binders among hemo-
dialysis patients and to explore the potentially modifiable
factors that are associated with low phosphate binder ad-
herence using a new structured questionnaire specially
designed for the PROHEMO.
Methods
The present cross-sectional study was performed using
the baseline data of patients enrolled in the second phase
of the Prospective Study of the Prognosis of Chronic
Hemodialysis Patients (PROHEMO) from January 2010 to
December 2010. The PROHEMO is an ongoing prospect-
ive cohort study of adult hemodialysis patients receiving
treatment at four satellite dialysis units in the city of
Salvador, BA, Brazil [17]. The Institutional Review
Board of the Medical School of the Federal University
of Bahia approved the study protocol, and all of the
patients provided informed consent to participate.
Data on adherence to phosphate binders were obtained
for 581 patients through face-to-face interviews, using a
structured questionnaire specially designed for the PRO
HEMO (Additional file 1). A total of 502 patients reported
that they had been prescribed a phosphate binder by a
nephrologist, and this information was confirmed by re-
viewing their medical records. These 502 patients consti-
tuted the sample for this study.
The patients were categorized as adherents or non-
adherents to phosphate binders. To be considered adher-
ent, the patients had to report that they always used or
almost always used the prescribed phosphate binder when
consuming foods rich in phosphorus, such as milk, cheese,
yogurt, meat, chicken, fish, beans, lentils, chickpeas, soy-
beans, peas, ham, sausage, chocolate and soda. Addition-
ally, they had to report never or rarely missing taking the
phosphate binder with a meal rich in phosphorus during
the previous month.
The collection of demographic data, laboratory parame-
ters, comorbidities and other clinical variables was per-
formed as soon as the patients were enrolled in the study.
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supplemented with information provided by the patient
and the attending nephrologist. The laboratory values
were based on the pre-dialysis measurements. The dialysis
dose was determined by the single-pool Kt/V. To deter-
mine the economic class (A, B, C, D, E) of each patient,
the classification system of the Brazilian Institute of
Market Research (Abipeme) was used [18]. This classifica-
tion takes into account consumer goods, such as refrigera-
tors, televisions and telephones. Patients in classes D and
E were categorized as poor or very poor [18]. The items
used to calculate the generic score on the Portuguese ver-
sion of the Kidney Disease Quality of Life Short Form
(KDQOL-SF) were used to determine the mental compo-
nent summary (MCS) and the physical component sum-
mary (PCS) of health-related quality of life [19]. The
complete Portuguese version of the Center for Epidemio-
logical Studies Depression Index (CES-D) was used to as-
sess symptoms of depression [20].
The patients were asked about their understanding of
the correct time to take the phosphate binders relative to
the intake of foods rich in phosphorus, i.e., within 30 mi-
nutes after food intake or more than 30 minutes after food
intake. Intentional lack of adherence due to the patients’
beliefs regarding the reasons for taking the medication
was investigated by asking the patients if they had ever
stopped taking the phosphate binder because they felt bet-
ter or worse.
To assess social interaction and support, the patients’
responses to two separate questions were used. The pa-
tients were asked about the degree of satisfaction with the
time that they were able to spend with family and friends
and about the support that they received from family and
friends. The responses to these questions could vary from
“very dissatisfied” to “very satisfied.” Patients who res-
ponded “somewhat dissatisfied” or “very dissatisfied” were
compared with those who responded “somewhat satisfied”
or “very satisfied.” The patients were asked five questions
to assess their interactions with the staff of the dialysis
clinics. Two questions required a yes-or-no response
based on the patient’s perception of the explanations
provided by the dietitian and nephrologist regarding the
correct use of the phosphate binder. The other three ques-
tions were aimed to evaluate the patient’s satisfaction with
the care provided by the staff, the patient’s perception of
the support provided by the staff or coping with the dis-
ease and the patient’s perception that he/she received en-
couragement from the staff to be independent as possible.
The level of satisfaction with care was classified into three
categories: “regular to very poor,” “good” and “very good
to the best,” with “good” being the reference category. The
patient’s perception of the support and encouragement
provided by the staff was rated on a five-point Likert scale
ranging, from “definitely true” to “definitely false.” Patientswho responded “definitely true” or “mostly true” were com-
pared with those who responded “don’t know,” “mostly
false” or “definitely false.”
Statistical analysis
The results are expressed as mean ± SD or as median and
interquartile range (IQR) for continuous variables and as
percentage for categorical variables. To test for differences
between groups, the chi-square or Fisher’s exact test
was used for categorical variables, and the t-test or
the Mann–Whitney test was used for quantitative variables.
Two groups of adjusted logistic regression models were
used to assess associations of non-adherence to the phos-
phate binder with patient’s characteristics, the understand-
ing and beliefs of the patients about the use of the
phosphate binder and personal interactions. The first
group of adjusted logistic regression models (minimally
adjusted models) included age, race, sex, education, eco-
nomic class, living with family, marital status, years on
dialysis and dialysis by catheter. The second group of
models (extensively adjusted models) included cerebro-
vascular disease, diabetes, heart failure, ischemic heart
disease, peripheral vascular disease, physician-diagnosed
depression, depression symptom score, cancer, PTH,
serum phosphorus, blood hemoglobin, albumin-corrected
serum calcium, serum creatinine and the co-variables in-
cluded in the minimally adjusted models. Binary indicator
variables were used to address missing categorical covari-
ate information. All of the analyses were performed using
SPSS software, version 21 for Mac.
Results
A total of 330 of the 502 patients (65.7%) were considered
non-adherent to phosphate binders. The most common
phosphate binders prescribed were sevelamer hydrochloride
(277/502 patients, 55.2%) and calcium carbonate (159/502,
31.7%). A small number of patients were prescribed calcium
acetate (5/502; 1%) or a combination of sevelamer hydro-
chloride and calcium carbonate (7/502; 1.4%). A total of 54
of 502 patients (10.8%) said that although a nephrologist
had prescribed a phosphate binder, they did not use it, so
they did not answer the question about which phosphate
binder they were using.
Table 1 shows the characteristics of the patients by cat-
egory of phosphate binder adherence. Compared with the
group of adherents to phosphate binders, the group of
non-adherents to phosphate binders had a marginally sig-
nificantly higher percentage of men (66.3% vs. 57.6%,
P =0.058), a younger mean age (46.98 ± 13.25 yr vs. 49.21 ±
13.26 yr, P =0.074) and a lower median number of months
on dialysis (48.78 vs. 60.15, P =0.056). A significantly (P =
0.011) higher median PTH level was observed for non-
adherent patients than for adherent patients (398.0 pg/mL
[IQR = 150.70 pg/mL −726.60 pg/mL] vs. 252.20 pg/mL
Table 1 Sociodemographic characteristics, comorbidities






Age, years (mean ± SD) 46.98 ± 13.25 49.21 ± 13.26 0.074
% Non-white 90.6 87.8 0.326








CESD-score (mean ± SD) 14.00 ± 10.70 13.58 ± 10.72 0.691
% Social characteristics
Married 58.7 57 0.706
< High school 63.5 61.6 0.676
Working before dialysis 75.7 76.2 0.905
Working currently 17.3 12.8 0.186
Poor or very poor 48.9 41.5 0.116
Living with family 86.9 90.7 0.214
% Comorbidities
Heart failure 8.6 12.2 0.197
Cerebrovascular disease 5.5 2.3 0.103




Peripheral vascular disease 3.3 4.1 0.669
Ischemic heart disease 9.4 9.9 0.868






10.49 ± 1.96 10.78 ± 1.62 0.096
Albumin, g/dL
(mean ± SD)
3.74 ± 0.52 3.80 ± 0.36 0.232
a Calcium, mg/dL
(mean ± SD)
8.91 ± 0.84 8.94 ± 1.09 0.708
Phosphorus, mg/dL
(mean ± SD)








Ca x P product 48.73 ± 13.34 50.46 ± 15.30 0.190
a calcium corrected for serum albumin.
IQR interquartile range.
Number with missing data: working before dialysis (1); working currently
(1); very poor (6); living with family (1); heart failure (4); cerebrovascular
disease (1); diabetes (1); depression (2); peripheral vascular disease
(2); ischemic heart disease (1); cancer (2); PTH (4).
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sion symptom scores determined by the CES-D were very
similar between adherence categories (14.0 ± 10.7 for non-
adherent patients and 13.6 ± 10.7 for adherent patients,
P = 0.691). Small differences by adherence category were
also observed for the means of Kt/V, PCS and MCS (data
not shown in the table).Almost all of the adherent patients to phosphate binders
(169/172) and approximately 80% (257/330) of those who
were non-adherents to phosphate binders reported that
a doctor had explained how to use the medication
(P <0.001). Almost 70% (119/172) of the adherent patients
and almost 60% (84/330) of the non-adherent patients
said that a dietitian had explained how to use the medica-
tion (P <0.001).
More than a half of the patients studied (264/502) never
took the phosphate binder when eating hemodialysis
snacks, although most of them (85%; 426/502) ate foods
rich in phosphorus as hemodialysis snacks. Almost 30%
(145/502) of the patients said that they usually forgot to
take the phosphate binder with snacks.
Regarding the comprehension of phosphate binder
use, almost 90% (437/502) of the patients said that they
did not take the phosphate binder when eating foods
with very low phosphorus content. Approximately 40%
of the patients (195/502) thought that they were sup-
posed to take the phosphate binder when eating foods
rich in phosphorus, 43.62% (219/502) thought that they
had to take it with their main meals (independent of the
phosphorus intake), and 6.77% (34/510) of the patients
said that they did not understand when to take the phos-
phate binder. In univariate analysis, none of the patients
in the adherent group (0/172) and 10% (34/330) in the
non-adherent group (P <0.001) did not understand how
to use the phosphate binder.
To assess another comprehension item of phosphate
binder use the patient was asked about the time to take
the medication after a meal rich in phosphorus. In the
univariate analysis, more than 60% of the patients in the
adherent group (107/172) said that they never took the
phosphate binder more than 30 minutes after such a meal,
and almost half of the patients (155/330) in the non-
adherent group said the same thing (P <0.001).
Almost 15% (31/216) of patients who were non-
adherents and approximately 6% (9/153) of the adherents
to the phosphate binder therapy reported that they always
or almost always stopped taking the phosphate binder on
their own initiative after feeling worse (P =0.031). In ad-
dition, 9.5% (25/264) of non-adherent patients and almost
2.5% (4/171) of adherents reported that they always or al-
most always stopped taking the phosphate binder on their
own initiative after feeling better (P <0.001). The patients
were also asked whether they had stopped taking the phos-
phate binder because they did not have the medication; al-
most 12% (39/330) of non-adherent patients and almost
10% (16/172) of adherents reported that they always or al-
most always stopped taking the phosphate binder for this
reason (P <0.001). No difference between the adherents
and non-adherents was observed in the univariate analysis
with regard to stopping phosphate binder use on one’s own
initiative associated with any specific symptom (P =0.510).
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tions between patient characteristics and non-adherence
to the phosphate binder. More years on dialysis and serum
phosphorus >5.5 mg/dL (compared to 3.5-5.5 mg/dL)
were associated with lower odds of non-adherence to the
phosphate binder in both the minimally and extensively
adjusted logistic regression models. In the extensively
adjusted model, greater odds of non-adherence were ob-
served for patients with higher PTH levels and cerebro-
vascular disease.
Table 3 shows the minimally and extensively adjusted lo-
gistic regressions for the association of the odds of non-
adherence to the phosphate binder with the factors deemed





Age per each 10 years 0.
Female vs. male 1.
Non-white vs. white 1.
Less than high school vs higher 1.
Poor/very poor vs. higher economic class 1.
Married (yes vs. no) 1.
Living with family (yes vs. no) 0.
Years on dialysis (each 2 years) 0.
Catheter as vascular access (yes vs. no) 1.




Ischemic heart disease 0.
Peripheral vascular disease 0.
Physician-diagnosed depression 1.
Depression score by CES-D* ≥18 vs. lower 0.
Cancer 1.
Laboratory variables
PTH (per 300 pg/mL higher) 1.
Serum phosphorus (<3.5 vs. 3.5-5.5 mg/dL) 0.
Serum phosphorus (>5.5 vs. 3.5-5.5 mg/dL) 0.
Serum calcium (per 1 mg/dL higher) 0.
Hemoglobin (<11 vs. ≥11 g/dL) 0.
Serum albumin (<3.5 vs. ≥3.5 g/dL) 1.
Serum creatinine (per 1 mg/dL higher) 0.
CES-D Center for Epidemiological Studies Depression Scale.
Minimally adjusted odds ratios were adjusted for age, sex, race, education, econom
by catheter.
Extensively adjusted odds ratios were adjusted for all listed variables.PB use, the patient’s beliefs about PBs, not having the medi-
cation, interactions between patients and their families and
interactions between patients and the staff.
Patients’ attitudes about and understanding of the
appropriate time to take the phosphate binder
The use of a phosphate binder more than 30 minutes after
eating foods rich in phosphorus (always or almost always
compared with rarely or never) was significantly associ-
ated with phosphate binder non-adherence in both the
minimally adjusted model (OR, 5.98; 95% confidence
interval (CI), 2.03-17.58) and the extensively adjusted
model(OR, 6.15; 95% CI, 2.04-18.50). There was no differ-
ence in the frequency of non-adherence between patientstient characteristics and non-adherence to phosphate
dds ratios (95% Confidence intervals)
inimally adjusted Extensively adjusted
88 (0.76-1.02) 0.87 (0.73-1.04)
53 (1.03-2.29) 1.48 (0.94-2.33)
24 (0.66-2.33) 1.28 (0.67-2.47)
09 (0.71-1.70) 1.15 (0.73-1.82)
20 (0.78-1.84) 1.23 (0.78-1.94)
09 (0.72-1.64) 1.07 (0.70-1.65)
65 (0.34-1.26) 0.64 (0.32-1.27)
91(0.84-0.99) 0.87 (0.80-0.95)
87 (0.82-4.28) 2.10 (0.85-5.15)
86 (0.93-8.77) 3.30 (1.03-10.61)
69 (0.41-1.18) 0.71 (0.40-1.29)
77 (0.41-1.44) 0.84 (0.43-1.65)
99 (0.52-1.93) 1.06 (0.52-2.20)
82 (0.30-2.26) 0.87 (0.29-2.63)
15 (0.47-2.80) 1.17 (0.46-3.01)
88 (0.57-1.37) 0.90 (0.57-1.44)
03 (0.36-2.96) 1.09 (0.37-3.23)
11 (0.99-1.24) 1.14(1.01-1.28)
43 (0.19-0.93) 0.50 (0.22-1.13)
50 (0.33-0.75) 0.53 (0.34-0.82)
99 (0.81-1.22) 1.02 (0.82-1.27)
98 (0.67-1.45) 0.94 (0.62-1.41)
48 (0.93-2.35) 1.50 (0.91-2.50)
95 (0.89-1.00) 0.97 (0.91-1.04)
ic class, marital status, living with family, years on dialysis and dialysis
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binder should be used after the main meals and the pa-
tients who thought that the drug should be used after
phosphorus intake in the minimally (OR, 1.18; 95%CI,
0.78-1.77) or extensively adjusted logistic regression mo-
dels (OR, 1.19; 95% CI, 0.76-1.85) (data not shown in
Table 3). The analysis comparing the patients who did not
understand phosphate binder use and those who believed
that they should take the drug after main meals was in-
accurate because of the small percentage of patients whoTable 3 Adjusted associations of patient’s attitudes and belie
Patient’s attitudes and beliefs
Patient’s attitude regarding or understanding of the time to take the p
Rarely or never take the PB > 30 minutes after meals
Frequently take the PB > 30 minutes after meals
Always or almost always take the PB >30 minutes after meals
Patient’s beliefs about stopping PB use after feeling better
Rarely or never stopped
Frequently stopped
Always or almost always stopped
Patient’s beliefs about stopping PB use after feeling worse
Rarely or never stopped
Frequently stopped
Always or almost always stopped
Patient’s report of stopping PB used because he/she did not have the m
Rarely or never stopped
Frequently stopped
Always or almost always stopped
Patient-family interactions
bSatisfied with time spent with family and friends
bSatisfied with support provided by family and friends
Patient-staff interactions
c Satisfaction with the care provided by the hemodialysis staff
Good
Very poor to regular
Very good to the best
dDialysis staff improved the patient’s ability to cope with the disease
dDialysis staff encouraged the patient to be independent
eNephrologist explained PB use
eDietitian explained PB use
PB phosphate binder.
aMinimally adjusted odds ratios were adjusted for age, race, sex, education, econom
catheter. Extensively adjusted odds ratios were adjusted for cerebrovascular disease
physician-diagnosed depression, depression score, cancer, PTH, albumin-corrected s
of the co-variables included in the minimally adjusted model.
bPatient responses were unsatisfied and very unsatisfied compared with satisfied an
c Patient response was very poor to regular compared with very good to the best.
d Patient response was definitely true or mostly true (positive responses) compared
e Patient response was yes (positive response) compared with no.did not understand in both groups. It should be noted
that in the adherent group, no patients reported not
understanding.
Patient’s beliefs
There was an association between phosphate binder non-
adherence and stopping the phosphate binder after feeling
better (always or almost always compared with rarely or
never) in the minimally (OR, 4.21; 95% CI, 1.41-12.54)
and extensively adjusted logistic regression models (OR,fs with non-adherence to phosphate binder use
Odds ratioa of Non-adherence(95% Confidence interval)
Minimally adjusteda Extensively adjusteda
hosphate binder
Ref = 1 Ref = 1
0.94 (0.52-1.68) 0.87 (0.47-1.61)
5.98 (2.03-17.58) 6.15 (2.04-18.50)
Ref = 1 Ref = 1
1.57 (0.61-4.02) 1.47 (0.55-3.91)
4.21 (1.41-12.54) 4.54 (1.45-14.25)
Ref = 1 Ref = 1
0.82 (0.30-2.27) 0.66 (0.23-1.91)
7.94 (1.80-35.06) 7.26 (1.62-32.55)
edication
Ref = 1 Ref = 1
1.35 (0.68-2.68) 1.29 (0.63-2.65)
3.57 (0.75-17.01) 2.77 (0.57-13.47)
0.97 (0.60-1.57) 1.05 (0.62-1.77)
0.89 (0.49-1.61) 0.83 (0.44-1.58)
Ref = 1 Ref = 1
1.11 (0.60-2.04) 1.25 (0.65-2.38)
1.06 (0.69-1.63) 1.13 (0.71-1.80)
0.62 (0.25-1.50) 0.67 (0.26-1.70)
0.52 (0.32-0.87) 0.52 (0.30-0.90)
0.22 (0.62-0.78) 0.20 (0.05-0.73)
0.96 (0.62-1.47) 1.11 (0.69-1.79)
ic class, living with family, marital status, years on dialysis and dialysis by
, diabetes, heart failure, ischemic heart disease, peripheral vascular disease,
erum calcium, serum phosphorus, blood hemoglobin, serum creatinine and all
d very satisfied.
with do not know and mostly or definitely false.
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after feeling worse (always or almost always compared
with rarely or never) was significantly associated with
phosphate binder non-adherence in both the minimally
(OR, 7.94; 95% CI, 1.80-35.06) and extensively adjusted
models (OR, 7.26; 95% CI, 1.62-32.55).
Patient reports of stopping the use of phosphate binder
because they did not have the medication
As shown in Table 3, patients non-adherent to phosphate
binder (PB) were more likely to report that they stopped
the use of PB because they did not have the medication,
but the difference was not statistically significant. The ex-
tensively adjusted odds of a patients refer that stopped
phosphate binder always or almost always (compared with
rarely or never) because he/she did not have the medica-
tion were approximately 2.8 times higher in the group of
non-adherents than in the group of adherents to phos-
phate binder (OR, 2.77; 95% CI, 0.57-13.47).
Patient-family interactions
There was no statistically significant association between
the patient’s satisfaction with the time spent with family
and friends (very satisfied or satisfied versus unsatisfied or
very unsatisfied) and non-adherence to phosphate binder
use in either the minimally (OR, 0.97; 95% CI, 0.60-1.57)
or extensively adjusted models (OR, 1.05; 95% CI, 0.62-
1.77). Weak and statistically non-significant association
with non-adherence to phosphate binder was observed for
satisfaction with the support of family and friends (very
satisfied or satisfied versus unsatisfied or very unsatisfied)
in the minimally (OR, 0.89; 95% CI, 0.49-1.61) and exten-
sively adjusted logistic regression models (OR, 0.83; 95%
CI, 0.44-1.58).
Patient-staff interaction
There was also no statistically significant association be-
tween satisfaction with the care provided by the
hemodialysis staff (good, very good, excellent and the best
versus very bad, bad and fair) and non-adherence to phos-
phate binder use in the minimally (OR, 1.06; 95% CI, 0.69-
1.63) or extensively adjusted logistic regression models
(OR, 1.13; 95% CI, 0.71-1.80). The belief that the dialysis
staff supported the patients with coping with the disease
(definitely true or mostly true versus do not know, mostly
false or definitely false) was weakly associated (not statisti-
cally significant) with lower odds of non-adherence in the
minimally (OR, 0.62; 95% CI, 0.25-1.50) and extensively
adjusted logistic regression models (OR, 0.67; 95% CI,
0.26-1.70). The belief that the dialysis staff encouraged the
patient’s independence (definitely true or mostly true ver-
sus do not know, mostly false or definitely false) was sig-
nificantly associated with lower odds of non-adherence in
both the minimally (OR, 0.52; 95% CI, 0.32-0.87) andextensively adjusted models (OR, 0.52; 95% CI, 0.30-
0.90). Having a nephrologist explain the use of the phos-
phate binder (yes versus no) was strongly associated with
lower odds of non-adherence in both the minimally (OR,
0.22; 95% CI, 0.62-0.78) and extensively adjusted models
(OR, 0.20; 95% CI, 0.05-0.73). There was no association
between having a dietitian explain PB use (yes versus no)
and phosphate binder non-adherence in the minimally
(OR, 0.96; 95% CI, 0.62-1.47) or extensively adjusted logis-
tic regression models (OR, 1.11; 95% CI, 0.69-1.79).Discussion
Similar to previous studies, this study showed that only a
small number, approximately one-third, of the patients
studied were adherent to the phosphate binder regimen
[16]. It is possible that this low adherence rate was associ-
ated with the phosphate binder having to be taken during
meals rich in phosphorus, interfering with social habits
and individual lifestyles and increasing the burden of daily
pills [14,15].
Karamanidou et al. found a high prevalence of phos-
phate binder non-adherence. In their systematic review,
the percentage of non-adherent patients ranged from 22%
to 74% (mean 51%) [16]. This large variability can be
explained by the different methodologies used to measure
adherence (such as self-reports, the serum phosphorus
level, pill counts and others) and by the various definitions
of adherence used in these studies [16]. Furthermore, this
systematic review also showed that when adherence was
assessed using the serum phosphorus level, the median
percentage of patients considered non-adherent was 58%,
but that this was 31% when assessed by self-reports [16].
However, the percentage of patients considered non-
adherent in our study, assessed by self-reports, was higher
than the median reported above. It is important to note
that in our study, adherence was defined based on two dif-
ferent questions asked at different times during the inter-
view, to avoid incorrect interpretations and to test and
confirm that the patient had really understood the ques-
tions. This design might have been responsible for the
higher non-adherence rate.
Another aim of our study was to expand the under-
standing of the potentially modifiable factors that are asso-
ciated with non-adherence to phosphate binder use. Our
study calls attention to several factors that are related to
the patients themselves and to patient-dialysis staff inter-
actions, rather than social, demographic, laboratory or
clinical factors. Our study revealed that health beliefs,
knowledge/understanding of medication use and the pa-
tient’s perception that the nephrologist had explained
phosphate binder use and that the hemodialysis staff had
encouraged them to be independent were associated with
phosphate binder adherence.
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ings”) about a medication, such as the potential adverse ef-
fects and benefits of taking it [14-16,21]. Although no
specific symptoms from the PROHEMO adherence ques-
tionnaire were associated in our study with non-adherence,
stopping phosphate binder use on one’s own initiative after
“feeling better” or “feeling worse” was associated with non-
adherence. It is possible that a greater focus on patient-
dialysis staff interactions could eliminate the barriers,
doubts and myths related to phosphate binder use and that
the treatment benefits could be enhanced by improving
adherence in this manner. Other studied factors could
reinforce the importance of patient-dialysis staff interac-
tions in determining phosphate binder adherence. These
factors include knowledge/understanding of medication
use and the patient’s perception that the nephrologist has
explained phosphate binder use and that the hemodialysis
staff has encouraged the patient to be independent.
Most of the sociodemographic factors assessed in our
study were not associated with adherence to phosphate
binders. Some studies have shown that older age is associ-
ated with higher levels of adherence [16,21]. In our study,
age was not associated with adherence in multivariate ana-
lysis, although univariate analysis showed a marginally sig-
nificant association between older age and adherence.
None of the laboratory variables, except for the phos-
phorus and PTHi levels, were associated with adherence
to phosphate binders. The extensively adjusted multivari-
ate analysis showed that phosphorus levels greater than
5.5 mg/dL, compared with levels in the range of 3.5-
5.5 mg/dL, were associated with adherence to phosphate
binders. Thus, patients with higher phosphorus levels
seem to be more adherent if the phosphorus level and ad-
herence are studied at the same time point. This associ-
ation might only reflect that patients who have higher
phosphorus levels use phosphate binders because they are
strongly advised to do so or that patients who use phos-
phate binders feel freer to eat more foods that are rich in
phosphorus, thus requiring better dietary counseling. We
could not determine the cause of this association because
our study did not evaluate daily phosphorus intake. Higher
PTHi levels were also associated with non-adherence, and
this association most likely reflects secondary hyperpara-
thyroidism as a consequence of permanent higher levels
of phosphorus in these patients [22].
Two other hypotheses assessed in our study were that
poor health-related quality of life and symptoms of depres-
sion would be associated with phosphate binder non-
adherence, but we did not find evidence supporting these
hypotheses. Regarding clinical variables, comorbidities, ex-
cept for cerebrovascular disease, were also not associated in
our study with non-adherence. It is possible that cerebro-
vascular disease was associated with non-adherence be-
cause cerebrovascular disease can reduce a patient’sautonomy and the independence necessary to self-medi-
cate, which appears to be important in phosphate binder
adherence. More time on hemodialysis was associated with
better adherence, possibly reflecting the importance of time
in patient-dialysis staff interactions in terms of patients’ ac-
ceptance and knowledge of the disease and therapy.
Moreover, the investigated social aspects were not asso-
ciated in our study with phosphate binder adherence. In
Brazil, the government usually provides sevelamer hydro-
chloride, and in some cities, such as Salvador, calcium car-
bonate is also provided, and it appears that not having the
medicine is more directly related to the level of govern-
ment, personal or family organization than to the patients’
ability to afford the drug.
Our study had some limitations. One limitation was the
methodology and its subjectivity, due to self-reports and
interviewer interpretations. To the best of our knowledge,
there are no validated questionnaires available to evaluate
the degree of adherence to phosphate binders and one of
the contributions of this study is a new applicable ques-
tionnaire that can be used in future research. Because the
interviews were conducted by only one researcher, differ-
ent interpretations were at least minimized. Another fac-
tor was the cross-sectional nature of the study, which
made it impossible to establish cause-and-effect relation-
ships for the observed associations. Other relevant factors
were that the patients’ preferred phosphate binders were
not determined for the completely non-adherent patients,
and the tablets’ tastes and sizes were not objectively de-
scribed in the questionnaire, although they could be bar-
riers to phosphate binder adherence. Our study did not
explore the personality characteristics and regimen com-
plexity that might be important in determining adherence
to phosphate binder therapy [23].
Additional high-quality studies are needed to explore bar-
riers to phosphate binder adherence in greater detail and
we expect that the questionnaire used, which was devel-
oped to provide a comprehensive assessment of adherence
to phosphate binder by hemodialysis patient, will stimulate
new investigations and more systematic assessment of
phosphate binder adherence in hemodialysis setting.
To the best of our knowledge, the sample size used in
this study was the largest used to date to assess phos-
phate binder adherence based on self-reports. Although
a large sample size is important, it is possible that the re-
sults were influenced by Brazil’s health care system pro-
viding both of the most commonly prescribed phosphate
binders (calcium carbonate and sevelamer hydrochlor-
ide). Therefore, it is not possible generalize these results
to other health care systems.
Conclusion
Our study suggests that almost 70% of hemodialysis pa-
tients are phosphate binder non-adherent, and if the
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aspects seem not to be associated with non-adherence. It
appears that some of the identified potentially modifiable
factors can be improved by optimizing the attention paid
to patients by the staff. A new questionnaire was pro-
posed and the knowledge gained by the responses pro-
vided by the patients should be useful to guide
interventions aimed at improving adherence and ensure
the correct use of the medication.
Additional file
Additional file 1: Phosphate Binder Adherence PROHEMO
Questionnaire.
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